{
  "docId": "019de075-6448-707d-82ec-cbbeebb7feb3",
  "docSlug": "1eef6abd03697885c8a70f789c554a37",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 23,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "Clinical trial identifier NCT05873686 is provided.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-6448-707d-82ec-cbbeebb7feb3/20",
  "deckHref": "/decks/019de075-6448-707d-82ec-cbbeebb7feb3",
  "deckJsonHref": "/decks/019de075-6448-707d-82ec-cbbeebb7feb3.json",
  "deckAnchorHref": "/decks/019de075-6448-707d-82ec-cbbeebb7feb3#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.035,
        "w": 0.378,
        "x": 0.046,
        "y": 0.143
      },
      "kind": "paragraph",
      "text": "Patients with advanced solid tumors",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7693cc1f-4ef6-4227-a089-4a2096643520",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.026,
        "w": 0.339,
        "x": 0.33,
        "y": 0.237
      },
      "kind": "source-note",
      "text": "Clinicaltrials.gov NCT05873686",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5378e2f7-d90b-49f5-8414-6db6a9b5305d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.588,
        "w": 0.52,
        "x": 0.24,
        "y": 0.289
      },
      "kind": "table",
      "text": "Phase 1a Dose Escalation\nStarting dose of 20 mg, QD\nPrimary Objective:\nSelect doses/schedules for Phase 1b\nKey Endpoints:\nAssess Pharmacokinetics, pharmacodynamics, lab abnormalities, dose limiting toxicities",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0d50d26-d4d0-4254-9c19-d67f64ac9e5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.755,
        "x": 0.046,
        "y": 0.068
      },
      "kind": "title",
      "text": "NXP900: Phase 1a Expected to Begin in 3Q2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "baf36e89-edb6-4fa5-9b7b-863445cf8d15",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 20,
      "from": 18,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "7e447b5d-aa17-4faf-88b6-6d6dc58b352b",
      "evidence": "The deck presents data on the significant single agent activity of NXP900 in squamous cell cancers.",
      "position": 1,
      "objective": "Present NXP900 as a potential game-changer in squamous cell cancers",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}